NNovo Nordisk Read More Novo’s Denecimig Gets CHMP Nod for Hemophilia A in the European Union2026-09-18 Novo NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
NNovo Nordisk Read More NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen2026-09-17 Chief executive Mike Doustdar said the recommendation builds on more than 40 years of haemophilia work. In FRONTIER…
NNovo Nordisk Read More Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with hemophilia A as published in the Journal of Thrombosis and Haemostasis2026-09-17 FRONTIER5 data show investigational denecimig was well-tolerated with no unforeseen safety concerns after a direct switch from emicizumab,…
DDenmark Read More Between fjords and vineyards: the new frontier of wine is in Denmark2026-09-03 You might be interested in Holaluz: what happened to the ‘rooftop revolution’? Until now, Denmark has been a…
NNovo Nordisk Read More Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 20262026-07-11 Presented interim FRONTIER4 data evaluate the long-term safety and efficacy of investigational denecimig across once-weekly, once-every-two-weeks, and once-monthly…
NNovo Nordisk Read More Novo Nordisk’s Oral Ozempic Arrives as GLP-1 Data Opens New Frontier2026-05-03 Novo Nordisk enters a critical week with US launch of improved oral Ozempic, Lancet study showing semaglutide cuts…